IL6 and myelodysplastic syndrome: The ImmunAID and EU-MDS consortium studies demonstrated that ASC/NLRP3 inflammasome activation in LR-MDS patients reaches levels comparable to autoinflammatory disorders, with TNF levels predicting disease progression and IL-6/IL-1β correlating with transfusion requirements [96].